New frontiers in proton therapy: applications in cancers.

Cancer Commun (Lond) · 2019 · PMC6805548 · PMID 31640788

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendP = 0.06so close (0.05 < p ≤ 0.1)

Recently, a randomized trial [ 52 ] on TACE versus proton therapy for hepatocarcinoma showed a trend toward improved 2-year PFS (31% vs. 48%, P = 0.06) and 2-year LC (45% vs. 88%, P = 0.06) favoring proton therapy, although the difference was not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.